CORT Corcept Therapeutics Incorporat

11.66
-0.47  -4%
Previous Close 12.13
Open 12.26
Price To book 27.69
Market Cap 1.32B
Shares 113,187,000
Volume 971,137
Short Ratio 6.14
Av. Daily Volume 1,039,610

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved February 17, 2012.
Corlux - Korlym
Cushing's Syndrome
Phase 2 ongoing.
Mifepristone plus Abraxane
Triple-negative breast cancer
Phase 2 ongoing.
Mifepristone plus enzalutamide
Castration-resistant prostate cancer (CRPC)
Phase 1/2 data released December 10, 2016 - 4/21 partial responses.
Mifepristone in combination with eribulin
Cancer - triple-negative breast cancer
Phase 2 initiated 1Q 2016. Enrolling as of January 2017.
CORT125134
Solid tumors - cancer
Phase 2 trial initiated 2Q 2016. Data due by the end of 2017.
CORT125134
Cushing’s syndrome

Latest News

  1. Pharma Stock With Triple-Digit Growth Forming Blotchy Base
  2. ETFs with exposure to Corcept Therapeutics, Inc. : May 18, 2017
  3. Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate
  4. 4 of the Cheapest Biotech Stocks in the World
  5. Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : May 10, 2017
  6. Edited Transcript of CORT earnings conference call or presentation 1-May-17 9:00pm GMT
  7. Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress
  8. Corcept posts 1Q profit
  9. Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
  10. Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call
  11. Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View
  12. Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : April 25, 2017
  13. Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
  14. Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : April 24, 2017
  15. Here's Why Corecept Therapeutics Incorporated Had a Rough Day
  16. Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
  17. Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?
  18. Corcept (CORT) Strives to Commercialize Key Drug Korlym
  19. Corcept Therapeutices Eyes Another Double
  20. Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics